Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference
Rhea-AI Summary
Treace Medical Concepts (TMCI) announced new technological innovations to be showcased at the 2025 ACFAS Annual Scientific Conference in Phoenix, Arizona. The company introduced several advancements in their bunion treatment portfolio, including:
- Micro-Lapiplasty™ and Mini-Adductoplasty™ platforms with SpeedPlate™ MicroQuad™ implant for small incision approaches
- Two new 3D minimally invasive systems: Nanoplasty™ and Percuplasty™, complemented by SpeedAkin™ implant
- SpeedMTP™, combining SpeedPlate™ compression fixation with Fastpitch™ locking screws for arthritic great toe joint treatment
- IntelliGuide™ PSI cut guides, offering pre-op planning, patient-specific 3D-printed guides, and Bone Clone™ anatomic foot models
Positive
- Introduction of multiple new innovative medical technologies expanding product portfolio
- First-to-market position with IntelliGuide™ PSI personalized surgical system
- Enhanced minimally invasive surgical options potentially expanding market reach
Negative
- None.
Insights
Treace's new product innovations represent a comprehensive expansion of their bunion correction portfolio with strategic emphasis on minimally invasive techniques. The company is methodically addressing various surgeon preferences while maintaining their core focus on 3D bunion correction.
The Micro-Lapiplasty™ and Mini-Adductoplasty™ platforms demonstrate the evolution of their flagship technologies toward less invasive approaches, potentially addressing surgeon adoption barriers related to incision size while maintaining their differentiated 3D correction philosophy.
Most significant is the introduction of two completely new minimally invasive systems - Nanoplasty™ and Percuplasty™ - which strategically expands Treace's addressable market to include surgeons who favor MIS osteotomy techniques. This represents a calculated expansion beyond their traditional 3D correction approach into adjacent procedural methodologies.
Their SpeedMTP™ system for arthritic MTP joints demonstrates product line extension into complementary pathologies often encountered alongside bunions. The IntelliGuide™ PSI patient-specific instrumentation platform introduces reproducibility advantages while potentially creating recurring revenue opportunities through the planning services model.
The technological progression follows typical medical device lifecycle management - refining flagship products while developing adjacency opportunities that leverage existing sales channels. By serving the full spectrum from traditional to minimal approaches within their specialized niche, Treace appears to be executing a focused depth strategy rather than attempting category diversification.
Treace's innovation showcase demonstrates a nuanced understanding of the evolving surgical preference spectrum in bunion correction. The portfolio expansion addresses a crucial clinical reality: surgeons typically favor specific approaches based on training and experience.
The Nanoplasty™ and Percuplasty™ systems represent Treace's pragmatic acknowledgment that despite their advocacy for 3D correction principles, many surgeons remain committed to osteotomy-based approaches. These systems could significantly increase Treace's procedural penetration by providing instrumentation that standardizes historically technique-dependent MIS procedures.
The SpeedMTP™ fusion option acknowledges the clinical reality that approximately 20% of bunion patients present with arthritic MTP joints requiring fusion rather than preservation. This addresses a previous gap in their solution set.
Most notable is the IntelliGuide™ PSI patient-specific instrumentation platform, which introduces pre-operative planning sophistication previously uncommon in foot and ankle procedures. This technology transfer from larger joint reconstruction could address precision and reproducibility challenges, particularly relevant for less experienced surgeons.
By developing multiple procedural options while maintaining their core philosophical emphasis on 3D correction, Treace effectively accommodates varied surgical preferences without diluting their clinical differentiation. The comprehensive approach could accelerate adoption by reducing the need for surgeons to source multiple vendors for different bunion case types.
Expands market-leading position with new best-in-class bunion technologies
PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Phoenix, Arizona from March 27-30, 2025.
“We are excited to have another strong presence at ACFAS, highlighting our commitment to surgical podiatry and advancing our company’s focused mission to improve surgical outcomes for bunion patients.” said John T. Treace, CEO, Founder and Board Member of Treace. “We will showcase several new innovations in our expanding and comprehensive bunion portfolio and also look forward to sharing compelling clinical evidence on our flagship Lapiplasty® and Adductoplasty® procedures during podium presentations.”
Treace will feature next-generation technologies at its ACFAS exhibit booth and host surgeon training events on these innovations, including:
- Latest advancements in our flagship Lapiplasty® and Adductoplasty® platforms; Micro-Lapiplasty™ and Mini-Adductoplasty™ further enabled by our new SpeedPlate™ MicroQuad™ implant, delivering robust, stable fixation for these small incision approaches.
- Our two new 3D minimally invasive (MIS), instrumented and reproducible osteotomy systems: Nanoplasty™ is designed to expand and accelerate surgeon access to MIS osteotomies and is performed through a small, hidden incision on the side of the foot; and Percuplasty™ is designed to increase reproducibility and speed of percutaneous MIS osteotomy approaches, setting a new standard for surgeons who prefer this approach. Both systems are complemented by our new SpeedAkin™ implant used in Akin osteotomy procedures, which are typically performed in conjunction with MIS osteotomies.
- SpeedMTP™ provides surgeons with a unique and efficient fusion option to address bunion patients with arthritic great toe (MTP) joints. SpeedMTP™ combines our market leading SpeedPlate™ compression fixation technology with our Fastpitch™ locking screws to deliver an ultra-low profile and highly stable implant designed to support early weight bearing for these patients.
- IntelliGuide™ PSI cut guides for Lapiplasty® and Adductoplasty® are a first and only in the market, uniquely offering surgeons a pre-op plan, patient specific 3D-printed cut guide and Bone Clone™ anatomic foot model, all produced from the patient’s CT-scan. Our IntelliGuide™ PSI platform is leading a new era of personalized solutions for bunion and midfoot deformity corrections.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty®, Adductoplasty® and SpeedMTP™ procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
What new bunion treatment technologies did TMCI announce for 2025?
How does TMCI's new SpeedMTP™ system benefit bunion patients?
What makes TMCI's IntelliGuide™ PSI system unique in the market?
What are the key features of TMCI's new minimally invasive systems?
